| Abstract [eng] |
Aim: to review the literature and discuss the indications, contraindications and complications of biological therapy for inflammatory bowel disease that are commonly reported in the scientific literature. Review of the literature: The selection for scientific publications was made from 2024 01 16 to 2024 03 20. Scientific publications were selected from Pubmed, Cochrane, Ovid and Lithuanian law databases. The databases were searched in Lithuanian and English using keywords: ,,biological therapy“, ,,inflammatory bowel disease“, ,,indications“, ,,contraindications“, ,,side effects“, ,,adverse effect“. The review includes 60 articles that met requirements and were relevant to the topic. Results and conclusions: the indications for biologic therapy most frequently discussed in the literature are: refractory inflammatory bowel disease; moderate-to-severe cases; those with risk factors that worsen the prognosis; to keep the patient in remission for as long as possible; fistulising perianal Crohn‘s disease combined with fistula drainage. Contraindications: diagnosis of moderate to severe heart failure; active or latent infections, the most important of which are tuberculosis, hepatitis B and C, uncontrolled human immunodeficiency virus; history of cancer; history of neurological disease; history of hypersensitivity to biologics; history of recent vaccination with live vaccines. Additional precautions should be taken if the patient is pregnant and her pregnancy has entered the third trimester. Complications: reactions related to the infusion; cancer; infections due to immunosuppression; autoimmune disorders; neurological disorders; dermatological disorders; liver damage; immunogenicity against biologics. Knowledge of the new biologic drugs (ustekinumab, vedolizumab) is limited, so it is recommended that more attention be paid to their research. |
